

Benign Prostatic Hyperplasia (BPH) Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

<https://marketpublishers.com/r/B09D51B36E8MEN.html>

Date: May 2018

Pages: 144

Price: US\$ 3,680.00 (Single User License)

ID: B09D51B36E8MEN

Abstracts

Report Summary

Benign Prostatic Hyperplasia (BPH) Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Benign Prostatic Hyperplasia (BPH) Drugs industry, standing on the readers' perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Worldwide and Top 20 Countries Market Size of Benign Prostatic Hyperplasia (BPH) Drugs 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Benign Prostatic Hyperplasia (BPH) Drugs worldwide and market share by regions, with company and product introduction, position in the Benign Prostatic Hyperplasia (BPH) Drugs market

Market status and development trend of Benign Prostatic Hyperplasia (BPH) Drugs by types and applications

Cost and profit status of Benign Prostatic Hyperplasia (BPH) Drugs, and marketing status

Market growth drivers and challenges

The report segments the global Benign Prostatic Hyperplasia (BPH) Drugs market as:

Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)

Asia Pacific (China, Japan, India, Southeast Asia and Australia)

Latin America (Brazil, Argentina and Colombia)

Middle East and Africa

Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Alpha-blocker

Phosphodiesterase Type-5 Inhibitors

5-alpha-Reductase Inhibitors

Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Application Segment
Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers
and Market Analysis)

Hospitals

Clinics

Others

Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Manufacturers Segment
Analysis (Company and Product introduction, Benign Prostatic Hyperplasia (BPH)
Drugs Sales Volume, Revenue, Price and Gross Margin):

Astellas Pharma

Eli Lilly

GlaxoSmithKline

Sanofi

ADC Therapeutics

Bayer HealthCare

Bristol-Myers Squibb

Valeant Pharmaceuticals

Endo Pharmaceuticals

Foresee Pharmaceuticals

Madrigal Pharmaceuticals

Merck

Novartis

Spectrum Pharmaceuticals
Takeda Pharmaceuticals
Teva
Advaxis
ANI Pharmaceuticals
BHR Pharma

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS

- 1.1 Definition of Benign Prostatic Hyperplasia (BPH) Drugs in This Report
- 1.2 Commercial Types of Benign Prostatic Hyperplasia (BPH) Drugs
 - 1.2.1 Alpha-blocker
 - 1.2.2 Phosphodiesterase Type-5 Inhibitors
 - 1.2.3 5-alpha-Reductase Inhibitors
- 1.3 Downstream Application of Benign Prostatic Hyperplasia (BPH) Drugs
 - 1.3.1 Hospitals
 - 1.3.2 Clinics
 - 1.3.3 Others
- 1.4 Development History of Benign Prostatic Hyperplasia (BPH) Drugs
- 1.5 Market Status and Trend of Benign Prostatic Hyperplasia (BPH) Drugs 2013-2023
 - 1.5.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Trend 2013-2023

CHAPTER 2 NORTH AMERICA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Benign Prostatic Hyperplasia (BPH) Drugs in North America 2013-2017
- 2.2 Consumption Market of Benign Prostatic Hyperplasia (BPH) Drugs in North America by Regions
 - 2.2.1 Consumption Volume of Benign Prostatic Hyperplasia (BPH) Drugs in North America by Regions
 - 2.2.2 Revenue of Benign Prostatic Hyperplasia (BPH) Drugs in North America by Regions
- 2.3 Market Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in North America by Regions
 - 2.3.1 Market Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in United States 2013-2017
 - 2.3.2 Market Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in Canada 2013-2017
 - 2.3.3 Market Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in Mexico 2013-2017
- 2.4 Market Development Forecast of Benign Prostatic Hyperplasia (BPH) Drugs in

North America 2018-2023

2.4.1 Market Development Forecast of Benign Prostatic Hyperplasia (BPH) Drugs in North America 2018-2023

2.4.2 Market Development Forecast of Benign Prostatic Hyperplasia (BPH) Drugs by Regions 2018-2023

CHAPTER 3 NORTH AMERICA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole North America Market Status by Types

3.1.1 Consumption Volume of Benign Prostatic Hyperplasia (BPH) Drugs in North America by Types

3.1.2 Revenue of Benign Prostatic Hyperplasia (BPH) Drugs in North America by Types

3.2 North America Market Status by Types in Major Countries

3.2.1 Market Status by Types in United States

3.2.2 Market Status by Types in Canada

3.2.3 Market Status by Types in Mexico

3.3 Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs in North America by Types

CHAPTER 4 NORTH AMERICA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs in North America by Downstream Industry

4.2 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry in Major Countries

4.2.1 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry in United States

4.2.2 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry in Canada

4.2.3 Demand Volume of Benign Prostatic Hyperplasia (BPH) Drugs by Downstream Industry in Mexico

4.3 Market Forecast of Benign Prostatic Hyperplasia (BPH) Drugs in North America by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS

5.1 North America Economy Situation and Trend Overview

5.2 Benign Prostatic Hyperplasia (BPH) Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN NORTH AMERICA

6.1 Sales Volume of Benign Prostatic Hyperplasia (BPH) Drugs in North America by Major Players

6.2 Revenue of Benign Prostatic Hyperplasia (BPH) Drugs in North America by Major Players

6.3 Basic Information of Benign Prostatic Hyperplasia (BPH) Drugs by Major Players

6.3.1 Headquarters Location and Established Time of Benign Prostatic Hyperplasia (BPH) Drugs Major Players

6.3.2 Employees and Revenue Level of Benign Prostatic Hyperplasia (BPH) Drugs Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Astellas Pharma

7.1.1 Company profile

7.1.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.1.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharma

7.2 Eli Lilly

7.2.1 Company profile

7.2.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.2.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly

7.3 GlaxoSmithKline

7.3.1 Company profile

7.3.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.3.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline

7.4 Sanofi

7.4.1 Company profile

7.4.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.4.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Sanofi

7.5 ADC Therapeutics

7.5.1 Company profile

7.5.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.5.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of ADC Therapeutics

7.6 Bayer HealthCare

7.6.1 Company profile

7.6.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.6.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Bayer HealthCare

7.7 Bristol-Myers Squibb

7.7.1 Company profile

7.7.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.7.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb

7.8 Valeant Pharmaceuticals

7.8.1 Company profile

7.8.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.8.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Valeant Pharmaceuticals

7.9 Endo Pharmaceuticals

7.9.1 Company profile

7.9.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.9.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Endo Pharmaceuticals

7.10 Foresee Pharmaceuticals

7.10.1 Company profile

7.10.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.10.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of Foresee Pharmaceuticals

7.11 Madrigal Pharmaceuticals

7.11.1 Company profile

7.11.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.11.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross

Margin of Madrigal Pharmaceuticals

7.12 Merck

7.12.1 Company profile

7.12.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.12.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross

Margin of Merck

7.13 Novartis

7.13.1 Company profile

7.13.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.13.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross

Margin of Novartis

7.14 Spectrum Pharmaceuticals

7.14.1 Company profile

7.14.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.14.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross

Margin of Spectrum Pharmaceuticals

7.15 Takeda Pharmaceuticals

7.15.1 Company profile

7.15.2 Representative Benign Prostatic Hyperplasia (BPH) Drugs Product

7.15.3 Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross

Margin of Takeda Pharmaceuticals

7.16 Teva

7.17 Advaxis

7.18 ANI Pharmaceuticals

7.19 BHR Pharma

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS

8.1 Industry Chain of Benign Prostatic Hyperplasia (BPH) Drugs

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS

9.1 Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Drugs

9.2 Raw Materials Cost Analysis of Benign Prostatic Hyperplasia (BPH) Drugs

9.3 Labor Cost Analysis of Benign Prostatic Hyperplasia (BPH) Drugs

9.4 Manufacturing Expenses Analysis of Benign Prostatic Hyperplasia (BPH) Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Benign Prostatic Hyperplasia (BPH) Drugs-Global Market Status & Trend Report
2013-2023 Top 20 Countries Data

Product link: <https://marketpublishers.com/r/B09D51B36E8MEN.html>

Price: US\$ 3,680.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer
Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click
button on product page <https://marketpublishers.com/r/B09D51B36E8MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form
below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms
& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970

